INCLINE VILLAGE, Nev.,
July 30, 2020 /PRNewswire/ -- PDL
BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces
that it will release its second quarter 2020 financial results for
the period ended June 30, 2020, on
Thursday, August 6, 2020, after
market close. PDL's management will host a conference call
and webcast that day at 4:30 p.m. Eastern
time to discuss the operating and financial results and
recent developments. A slide presentation relating to the
call will be available via the webcast link on the PDL website at
http://www.pdl.com/.
Conference Call Details
We encourage participants to
pre-register for the conference call using the following link:
http://dpregister.com/10146007. Callers who pre-register will
be given a conference passcode and unique PIN to gain immediate
access to the call and bypass the live operator. Participants may
pre-register at any time, including up to and after the call start
time.
Those who choose not to pre-register can access the live
conference by dialing (866) 777-2509 from the United States or (412) 317-5413
internationally. The conference ID is 10146007. Please
dial in approximately 10 minutes prior to the start of the
call. A telephone replay will be available for one week
following the call and may be accessed by dialing (877)
344-7529 from the United
States, (855) 669-9658 from Canada or (412) 317-0088 internationally. The
replay passcode is 10146007.
To access the live and subsequently archived webcast of the
conference call, go to "Events & Presentations" on the
Company's website. Please connect to the website at least 15
minutes prior to the call to allow for any software download that
may be necessary.
About PDL BioPharma
Throughout its history, PDL's
mission has been to improve the lives of patients by aiding in the
successful development of innovative therapeutics and healthcare
technologies. PDL BioPharma was founded in 1986 as Protein
Design Labs, Inc. when it pioneered the humanization of monoclonal
antibodies, enabling the discovery of a new generation of targeted
treatments that have had a profound impact on patients living with
different cancers as well as a variety of other debilitating
diseases. In 2006, the Company changed its name to PDL
BioPharma, Inc.
As of December 2019, PDL ceased
making additional strategic transactions and investments and is
pursuing a formal process to unlock the value of its portfolio by
monetizing its assets and ultimately distributing net proceeds to
stockholders in the form of cash or equity.
For more information please visit https://www.pdl.com/
NOTE: PDL, PDL BioPharma, the PDL logo and associated
logos and the PDL BioPharma logo are trademarks or registered
trademarks of, and are proprietary to, PDL BioPharma, Inc. which
reserves all rights therein.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/pdl-biopharma-to-announce-second-quarter-2020-financial-results-on-august-6-2020-301103280.html
SOURCE PDL BioPharma, Inc.